STAGE IVA PROSTATE CANCER AJCC V8
Clinical trials for STAGE IVA PROSTATE CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVA PROSTATE CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IVA PROSTATE CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene test guides prostate cancer treatment: less or more hormone therapy?
Disease control OngoingThis study tests whether using a genetic test to personalize hormone therapy can improve outcomes for men with high-risk prostate cancer. For those with a low genetic risk, a shorter course of hormone therapy (12 months instead of 24) is compared to standard care. For those with …
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 17, 2026 04:40 UTC
-
Double-Drug attack shows promise against tough prostate cancer
Disease control OngoingThis study tests whether adding rucaparib to standard enzalutamide helps men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 61 men will receive either the combination or enzalutamide alone. The goal is to see if the combo delays can…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 17, 2026 04:37 UTC
-
New Triple-Drug cocktail aims to stall spread of prostate cancer
Disease control OngoingThis study tests a combination of three drugs (abiraterone, prednisone, and apalutamide) in 60 men with prostate cancer that has spread but hasn't yet been treated with hormone therapy. The goal is to see how long men can stay on treatment and how well it controls the cancer. Par…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
New drug combo targets hard-to-treat metastatic cancers
Disease control OngoingThis early-phase trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in people with advanced prostate, bladder, or kidney cancer that has spread. The goal is to find the safest dose and see if the combination can help control the cancer. About 65 adults wi…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:16 UTC
-
New combo therapy aims to shrink advanced tumors
Disease control OngoingThis study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other treatments (utomilumab, anti-OX40 antibody, and radiation) in people with advanced cancers that have spread. About 173 adults whose cancer has not responded to standard therapies…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:16 UTC
-
Shorter radiation blasts may tame prostate cancer with fewer side effects
Disease control OngoingThis study tests whether a shorter, higher-dose radiation schedule (hypofractionated) works as well as the standard longer course for prostate cancer patients who have had their prostate removed. About 186 men with stage I to IVA prostate cancer will be randomly assigned to one o…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Could a hormone therapy vacation help prostate cancer patients recover testosterone?
Disease control OngoingThis study looks at whether men with metastatic prostate cancer that has responded extremely well to hormone therapy can safely take a break from treatment. The goal is to see if pausing therapy allows their testosterone levels to return to normal, potentially improving quality o…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 15, 2026 11:54 UTC